

# Global Cell Therapy Manufacturing Market Set to Surge with a CAGR of 14.2% by 2033

*In 2022, the United States held a 42.1% share in North America, and it's projected to maintain its dominant position in the foreseeable future.*

NEWARK, DELAWARE, UNITED STATES OF AMERICA, October 24, 2023 /EINPresswire.com/ -- The size of the worldwide [cell therapy manufacturing industry](#) is anticipated to grow at a compound annual growth rate (CAGR) of 14.2% from 2023 to 2033, when it is valued at US\$ 4,134.48 million. By the end of 2033, the market is projected to be valued at approximately US\$ 15,634.67 million.



Several rare and life-threatening illnesses' treatment paradigms have changed due to the development of sophisticated medicines, which has also significantly impacted the biopharmaceutical sector. One of the main factors fueling the expansion of the [cell and gene therapy manufacturing market demand](#) is the advanced therapeutic landscape's explosive rise.

Request A Sample Copy of This Report:

<https://www.futuremarketinsights.com/reports/sample/rep-gb-15536>

The ratio of clinical successes to the number of clinical trials for cellular and gene-modified therapeutic items has improved, as shown in the healthcare sector. This is due to improved scientific and clinical knowledge of the safety hazards associated with using these drugs.

In response to a rise in player investments and the clinical success of additional medicines, some gene therapy firms are concentrating on production and commercialization. While planning the manufacturing process for gene therapy products, it is important to evaluate the current process, examine its scalability, and decide whether to manufacture internally or externally.

Key Takeaways:

In 2022, North America's cell therapy manufacturing industry expanded, with a CAGR of 43.5%.

In 2022, the United States developed the cell therapy manufacturing business with a share of 42.1%.

The cell therapy manufacturing industry grew considerably to US\$ 3,685.79 million in 2022.

The cell therapy manufacturing industry expanded with a CAGR of 10.7% between 2018 to 2022.

By 2033, China's cell therapy manufacturing industry is projected to develop with a CAGR of 22.1%.

By 2033, India's cell therapy manufacturing industry is projected to expand with a CAGR of 19.4%.

Japan's cell therapy manufacturing industry grew significantly, with a 5.3% share in 2022.

Australia's cell therapy manufacturing industry is likely to expand with a CAGR of 13.6% by 2033.

Germany's cell therapy manufacturing business grew, with a share of 6.8% in 2022

In 2022, based on source, autologous dominated the market, with a share of 56%.

In 2022, the cancer segment led the market, with a share of 31%, based on the indication.

Key Players' Strategies and Recent Developments:

The pharmaceutical business WuXi AppTec's contract development and manufacturing organization (CDMO), WuXi Advanced Therapies, said in May 2020 that it had increased its service capabilities to provide a fully integrated, closed-process CAR-T cell treatment platform.

Anti Biosciences Inc. entered into an exclusive collaboration and global license agreement in January 2022. Allogene Therapeutics Inc., a clinical-stage biotechnology firm that is at the forefront of the development of allogeneic CAR T products for cancer, is advancing multiplex gene silencing as a novel approach for creating next-generation allogeneic CAR T products.

Thermo Fisher paid US\$ 1.85 billion in January 2022 to purchase PeproTech, a producer of recombinant proteins such as growth factors and cytokines.

Charles River Laboratories bought Vigene Biosciences Inc. in May 2021 to expand its capacity for manufacturing cell and gene therapies.

Drive Your Business Growth Strategy: Purchase the Report for Key Insights!

<https://www.futuremarketinsights.com/checkout/15536>

Key players:

Merck KGaA  
Avantor, Inc.  
Cell Therapies Pty Ltd  
Thermo Fisher Scientific  
Charles River Laboratories  
Catalent, Inc  
Bio-Techne  
Cytiva  
Lonza  
The Discovery Labs  
BIOCENTRIC  
FUJIFILM Diosynth Biotechnologies

Key segments:

By Source:

Autologous  
Allogenic

By Indication:

HIV  
Autoimmune Disorders  
Immune Deficiencies  
Cancer  
Neurological Disorders

By Manufacturing Purpose:

Clinical  
Commercial  
Pre-clinical

By Route of Administration:

Topical  
Injectable  
Infusion  
Implantable Bio-Scaffold

By Cell Type:

Hematopoietic (Blood-Forming) Stem Cells (HSC)  
Skeletal Muscle Stem Cells  
Mesenchymal Stem Cells  
Lymphocytes  
Dendritic Cells  
Pancreatic Islet Cells  
CAR-T Cells

By End User:

Hospital Settings  
Intensive Outpatient Treatment Centers  
Academic and Research Institutes  
Specialty Clinics

By Region:

North America  
Latin America  
Europe  
South Asia  
East Asia  
Oceania  
Middle East and Africa (MEA)

Author:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

Explore FMI's related ongoing Coverage in the Healthcare Market Insights Domain

[Cell and Gene Therapy Manufacturing Market Size](#): The market is expected to reach US\$ 19.3 billion in 2023. With a CAGR of 29% from 2023 to 2033, the market is expected to reach a

valuation of US\$ 240 Billion.

## About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Ankush Nikam

Future Market Insights, Inc.

+91 90966 84197

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[YouTube](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/663772915>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.